logo

Acceleron Pharma, Inc (XLRN)



Trade XLRN now with
  Date
  Headline
1/8/2018 9:07:00 AM Acceleron Reports Preliminary Results From Part 1 Of ACE-083 Phase2 Trial In Patients With Facioscapulohumeral Dystrophy
11/15/2017 4:02:03 PM Acceleron Appoints Karen Smith To Its Board Of Directors
11/7/2017 7:20:10 AM Acceleron Pharma Posts Q3 Net Loss Was $25.5 Mln
9/20/2017 8:49:27 PM Acceleron Pharma Prices Underwritten Public Offering Of 5.41 Mln Shares At $37.00/shr
9/19/2017 4:23:33 PM Acceleron Announces Proposed Public Offering Of Common Stock
6/23/2017 2:33:05 AM Acceleron Provides Updated Results From Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes
6/1/2017 7:34:28 AM Celgene And Acceleron Complete Target Enrollment In MEDALIST; Expect Top-line Results From Phase 3 Studies In Mid-2018
5/8/2017 7:30:27 AM Acceleron Pharma Q1 Loss/shr $0.66 Vs. EPS $0.13 Prior Year
3/16/2017 7:02:42 AM Acceleron To Begin Phase 2 Trial Of ACE-083 In Charcot-Marie-Tooth Neuromuscular Disease And Host Educational Webinar
3/1/2017 7:11:40 AM Acceleron Pharma Q4 Loss/shr Narrows To $0.51 From $0.81 Last Year